Inherited metabolic disorders and cerebral infarction

Expert Review of Neurotherapeutics

Volumn 8, Issue 11, 2008, Pages 1731-1741

  Kalidas, Kavita ^a   Behrouz, Réza ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Cerebral infarction; Cerebrotendinous xanthomatosis; Fabry's disease; Familial hypercholesterolemia; Glutaric acidemia; Homocystinuria; MELAS; Metabolic disease; Methylmalonic acidemia; Ornithine transcarbamylase deficiency; Propionic academia; Stroke

Indexed keywords

ALPHA GALACTOSIDASE; ARGININE; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BENZOIC ACID; BETAINE; CARNITINE; CHENODEOXYCHOLIC ACID; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYANOCOBALAMIN; CYSTEINE; EZETIMIBE PLUS SIMVASTATIN; FOLIC ACID; GABAPENTIN; IDEBENONE; LAMOTRIGINE; METHIONINE; PHENOBARBITAL; PHENYLACETIC ACID; PHENYTOIN; PHOSPHODIESTERASE I; PYRIDOXINE; RIBOFLAVIN; SIMVASTATIN; UBIDECARENONE;

AUTOSOMAL RECESSIVE DISORDER; BRAIN INFARCTION; CEREBROTENDINOUS XANTHOMATOSIS; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; DYSTONIA; FABRY DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; GLUTARIC ACIDURIA TYPE 1; HOMOCYSTINURIA; HYPERAMMONEMIA; MELAS SYNDROME; METABOLIC DISORDER; METHYLMALONIC ACIDEMIA; PROPIONIC ACIDEMIA; REVIEW; SEIZURE; TANGIER DISEASE;

CEREBRAL INFARCTION; HUMANS; METABOLISM, INBORN ERRORS;

EID: 56049090279     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.11.1731     Document Type: Review

References (131)

1. Meschia JF, Case LD, Worrall BB et al. Family history of stroke and severity of neurologic deficit after stroke. Neurology 67, 1396-1402 (2006).
2. Varret M, Abifadel M, Rabès JP, Boileau C. Genetic heterogeneity of autosomal dominant hypercholesterolemia. Clin. Genet. 73, 1-13 (2008).
3. Norman D, Sun XM, Bourbon M, Knight BL, Naoumova RP, Soutar AK. Characterization of a novel cellular defect in patients with phenotypic homozygous familial hypercholesterolemia. J. Clin. Invest. 104, 619-628 (1999).
4. Yuan G, Wang J, Hegele RA. Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. CMAJ 174, 1124-1129 (2006).
5. Hobbs HH, Brown MS, Russell DW et al. Deletion in the gene for the low-density-lipoprotein receptor in a majority of French Canadians with familial hypercholesterolemia. N. Engl. J. Med. 317, 734-737 (1987).
6. Mishra SK, Bose TK, Das BS. Homozygous familial hypercholesterolaemia. Report of three cases. J. Assoc. Physicians India 39, 344-345 (1991).
7. Gagné C, Moorjani S, Brun D et al. Heterozygous familial hypercholesterolemia: relationship between plasma lipids, lipoproteins, clinical manifestations and ischaemic heart disease in men and women. Atherosclerosis 34, 13-24 (1979).
8. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 168, 1-14 (2003).
9. Sibley C, Stone NJ. Familial hypercholesterolemia: a challenge of diagnosis and therapy. Cleve. Clin. J. Med. 73, 57-64 (2006).
10. Marais AD, Firth JC, Blom DJ. Homozygous familial hypercholesterolemia and its management. Semin. Vasc. Med. 4, 43-50 (2004).
11. Rubba P, Mercuri M, Faccenda F et al. Premature carotid atherosclerosis: does it occur in both familial hypercholesterolemia and homocystinuria? Ultrasound assessment of arterial intima-media thickness and blood flow velocity. Stroke 25, 943-950 (1994).
12. Soljanlahti S, Autti T, Lauerma K et al. Familial hypercholesterolemia patients treated with statins at no increased risk for intracranial vascular lesions despite increased cholesterol burden and extracranial atherosclerosis. Stroke 36, 1572-1574 (2005).
13. Rodriguez G, Bertolini S, Nobili F et al. Regional cerebral blood flow in familial hypercholesterolemia. Stroke 25, 831-836 (1994).
14. Williams RR, Hunt SC, Schumacher MC et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am. J. Cardiol. 72, 171-176 (1993).
15. Huijgen R, Vissers MN, Defesche JC, Lansberg PJ, Kastelein JJ, Hutten BA. Familial hypercholesterolemia: current treatment and advances in management. Expert Rev. Cardiovasc. Ther. 6, 567-581 (2008).
16. Avis HJ, Vissers MN, Stein EA et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 27, 1803-1810 (2007).
17. Marais AD, Raal FJ, Stein EA et al. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis 197, 400-406 (2008).
18. Marais AD, Blom DJ, Firth JC. Statins in homozygous familial hypercholesterolemia. Curr. Atheroscler. Rep. 4, 19-25 (2002).
19. Alonso R, Mata N, Mata P. Benefits and risks assessment of simvastatin in familial hypercholesterolaemia. Expert Opin. Drug Saf. 4, 171-181 (2005).
20. Kastelein JJ, Akdim F, Stroes ES et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358, 1431-1443 (2008).
21. Makino H, Harada-Shiba M. Long-term effect of low-density lipoprotein apheresis in patients with homozygous familial hypercholesterolemia. Ther. Apher. Dial. 7, 397-401 (2003).
22. Banyai S, Banyai M, Falger J et al. Atorvastatin improves blood rheology in patients with familial hypercholesterolemia (FH) on long-term LDL apheresis treatment. Atherosclerosis 159, 513-519 (2001).
23. Møller AT, Jensen TS. Neurological manifestations in Fabry's disease. Nat. Clin. Pract. Neurol. 3, 95-106 (2007).
24. Giacomini PS, Shannon PT, Clarke JT, Jaigobin C. Fabry's disease presenting as stroke in a young female. Can. J. Neurol. Sci. 31, 112-114 (2004).
25. Mitsias P, Levine SR. Cerebrovascular complications of Fabry's disease. Ann. Neurol. 40, 8-17 (1996).
26. Crutchfield KE, Patronas NJ, Dambrosia JM et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 50, 1746-1749 (1998).
27. Grewal RP. Stroke in Fabry's disease. J. Neurol. 241, 153-156 (1994). • Good review of cerebrovascular manifestations of Fabry's disease.
28. Rolfs A, Böttcher T, Zschiesche M et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 366, 1794-1796 (2005).
29. Burlina AP, Manara R, Caillaud C et al. The pulvinar sign: frequency and clinical correlations in Fabry disease. J. Neurol. 255, 738-744 (2008).
30. Grewal RP, McLatchey SK. Cerebrovascular manifestations in a female carrier of Fabry's disease. Acta Neurol. Belg. 92, 36-40 (1992).
31. Ritter M, Dittrich R, Droste DW. Microembolus detection in four patients with Fabry's disease: further support for a primarily microangiopathic origin of early cerebrovascular symptoms. Eur. Neurol. 50, 141-145 (2003).
32. Mehta A, Ricci R, Widmer U et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur. J. Clin. Invest. 34, 236-242 (2004).
33. Desnick RJ, Brady R, Barranger J et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann. Intern. Med. 138, 338-346 (2003).
34. Wilcox WR, Banikazemi M, Guffon N et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet. 75, 65-74 (2004).
35. Moore DF, Altarescu G, Ling GS et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 33, 525-531 (2002).
36. Moore DF, Scott LT, Gladwin MT et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 104, 1506-1512 (2001).
37. Moghadasian MH, Salen G, Frohlich JJ, Scudamore CH. Cerebrotendinous xanthomatosis: a rare disease with diverse manifestations. Arch. Neurol. 59, 527-529 (2002). • Good review of cerebrotendinous xanthomatosis.
38. Valdivielso P, Calandra S, Durán JC, Garuti R, Herrera E, González P. Coronary heart disease in a patient with cerebrotendinous xanthomatosis. J. Intern. Med. 255, 680-683 (2004).
39. Joo IS, Cho PZ, Kim DI. A case of cerebrotendinous xanthomatosis associated with cerebral infarction. J. Korean Neurol. Assoc. 6, 91-96 (1988).
40. Potkin BN, Hoeg JM, Connor WE et al. Aneurysmal coronary artery disease in cerebrotendinous xanthomatosis. Am. J. Cardiol. 61, 1150-1152 (1988).
41. Shore V, Salen G, Cheng FW et al. Abnormal high density lipoproteins in cerebrotendinous xanthomatosis. J. Clin. Invest. 68, 1295-1304 (1981).
42. Panzenboeck U, Andersson U, Hansson M, Sattler W, Meaney S, Björkhem I. On the mechanism of cerebral accumulation of cholestanol in patients with cerebrotendinous xanthomatosis. J. Lipid Res. 48, 1167-1174 (2007).
43. Lorincz MT, Rainier S, Thomas D, Fink JK. Cerebrotendinous xanthomatosis: possible higher prevalence than previously recognized. Arch. Neurol. 62, 1459-1463 (2005).
44. Smithard A, Lamyman MJ, McCarthy CL, Gibbons CL, Cooke PJ, Athanasou N. Cerebrotendinous xanthomatosis presenting with bilateral Achilles tendon xanthomata. Skeletal Radiol. 36, 171-175 (2007).
45. Muhammed K, Nandakumar G, Saritha S. Cerebrotendinous xanthomatosis: need for early diagnosis. Indian J. Dermatol. Venereol. Leprol. 72, 364-366 (2006).
46. De Stefano N, Dotti MT, Mortilla M, Federico A. Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis. Brain 124, 121-131 (2001).
47. Berginer VM, Salen G, Shefer S. Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N. Engl. J. Med. 311, 1649-1652 (1984).
48. Verrips A, Wevers RA, Van Engelen BG et al. Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis. Metabolism 48, 233-238 (1999).
49. Bojanovski D, Gregg RE, Brewer HB Jr. Tangier disease. In vitro conversion of proapo-A-ITangier to mature APO-A-ITangier. J. Biol. Chem. 259, 6049-6051 (1984)
50. Tall AR, Wang N. Tangier disease as a test of the reverse cholesterol transport hypothesis. J. Clin. Invest. 106, 1205-1207 (2000).
51. Kolovou GD, Mikhailidis DP, Anagnostopoulou KK, Daskalopoulou SS, Cokkinos DV. Tangier disease four decades of research: a reflection of the importance of HDL. Curr. Med. Chem. 13, 771-782 (2006).
52. Oram JF. Tangier disease and ABCA1. Biochim. Biophys. Acta. 1529, 321-330 (2000).
53. Serfaty-Lacrosniere C, Civeira F, Lanzberg A et al. Homozygous Tangier disease and cardiovascular disease. Atherosclerosis 107, 85-98 (1994).
54. Brooks-Wilson A, Marcil M, Clee SM et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 22, 336-345 (1999).
55. Asztalos BF, Brousseau ME, McNamara JR, Horvath KV, Roheim PS, Schaefer EJ. Subpopulations of high density lipoproteins in homozygous and heterozygous Tangier disease. Atherosclerosis 156, 217-225 (2001).
56. Sinha S, Mahadevan A, Lokesh L et al. Tangier disease: a diagnostic challenge in countries endemic for leprosy. J. Neurol. Neurosurg. Psychiatry 75, 301-304 (2004).
57. Natowicz M, Kelley RI. Mendelian etiologies of stroke. Ann. Neurol. 22, 175-192 (1987). • Also a good review of stroke genetics.
58. Kraus JP, Janosík M, Kozich V et al. Cystathionine β-synthase mutations in homocystinuria. Hum. Mutat. 13, 362-375 (1999).
59. Varga EA, Sturm AC, Misita CP, Moll S. Cardiology patient pages. Homocysteine and MTHFR mutations: relation to thrombosis and coronary artery disease. Circulation 111, e289-e293 (2005).
60. Meschia JF, Brott TG, Brown RD Jr. Genetics of cerebrovascular disorders. Mayo Clin. Proc. 80, 122-132 (2005). •• Very concise review of stroke genetics.
61. Cruysberg JR, Boers GH, Trijbels JM, Deutman AF. Delay in diagnosis of homocystinuria: retrospective study of consecutive patients. BMJ 313, 1037-1040 (1996)
62. Buoni S, Di Bartolo RM, Molinelli M, Palmeri S, Zannolli R. Atypical BECTS and homocystinuria. Neurology 61, 1129-1131 (2003).
63. Clarke R, Lewington S. Homocysteine and coronary heart disease. Semin. Vasc. Med. 2, 391-399 (2002).
64. Casas JP, Bautista LE, Smeeth L et al. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet 365, 224-232 (2005).
65. Carson NAJ. Homocystinuria: clinical and biochemical heterogeneity. In: Inborn Errors of Metabolism in Humans. Cockburn F, Gitzelmann R (Eds). MTP Press Ltd, Lancaster, UK 53-67 (1982).
66. van Guldener C, Stehouwer CD. Homocysteine and large arteries. Adv. Cardiol. 44, 278-301 (2007).
67. Cardo E, Campistol J, Caritg J et al. Fatal haemorrhagic infarct in an infant with homocystinuria. Dev. Med. Child. Neurol. 41, 132-135 (1999).
68. Kelly PJ, Furie KL, Kistler JP et al. Stroke in young patients with hyperhomocysteinemia due to cystathionine β-synthase deficiency. Neurology 60, 275-279 (2003).
69. Weiss N, Demeret S, Sonneville R, Guillevin R, Bolgert F, Pierrot-Deseilligny C. Bilateral internal carotid artery dissection in cystathionine β-synthase deficiency. Eur. Neurol. 55, 177-178 (2006).
70. Bittles AH, Carson NA. Homocystinuria: studies on cystathionine beta-synthase, S-adenosylmethionine synthetase and cystathionase activities in skin fibroblasts. J. Inherit. Metab. Dis. 4, 3-6 (1981).
71. Chace DH, Hillman SL, Millington DS, Kahler SG, Adam BW, Levy HL. Rapid diagnosis of homocystinuria and other hypermethioninemias from newborns' blood spots by tandem mass spectrometry. Clin. Chem. 42, 349-355 (1996).
72. Mahfoud A, Domínguez CL, Pérez A, Rizzo C, Merinero B, Pérez B. Diagnosis and treatment of methylmalonic aciduria: a case report. Invest. Clin. 48, 99-105 (2007).
73. Chandler RJ, Venditti CP. Genetic and genomic systems to study methylmalonic acidemia. Mol. Genet. Metab. 86, 34-43 (2005).
74. Shigematsu Y, Hirano S, Hata I et al. Newborn mass screening and selective screening using electrospray tandem mass spectrometry in Japan. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 776, 39-48 (2002).
75. Coulombe JT, Shih VE, Levy HL. Massachusetts Metabolic Disorders Screening Program. II. Methylmalonic aciduria. Pediatrics 67, 26-31 (1981).
76. Nicolaides P, Leonard J, Surtees R. Neurological outcome of methylmalonic acidaemia. Arch. Dis. Child. 78, 508-512 (1998).
77. Matsui SM, Mahoney MJ, Rosenberg LE. The natural history of the inherited methylmalonic acidemias. N. Engl. J. Med. 308, 857-861 (1983).
78. Heidenreich R, Natowicz M, Hainline BE et al. Acute extrapyramidal syndrome in methylmalonic acidemia: "metabolic stroke" involving the globus pallidus. J. Pediatr. 113, 1022-1027 (1988).
79. Chakrapani A, Sivakumar P, McKiernan PJ, Leonard JV. Metabolic stroke in methylmalonic acidemia five years after liver transplantation. J. Pediatr. 140, 261-263 (2002).
80. Wajner M, Coelho JC. Neurological dysfunction in methylmalonic acidaemia is probably related to the inhibitory effect of methylmalonate on brain energy production. J. Inherit. Metab. Dis. 20, 761-768 (1997).
81. Roze E, Gervais D, Demeret S et al. Neuropsychiatric disturbances in presumed late-onset cobalamin C disease. Arch. Neurol. 60, 1457-1462 (2003).
82. Rashed MS, Ozand PT, Bucknall MP, Little D. Diagnosis of inborn errors of metabolism from blood spots by acylcarnitines and amino acids profiling using automated electrospray tandem mass spectrometry. Pediatr. Res. 38, 324-331 (1995).
83. Tanpaiboon P. Methylmalonic acidemia (MMA). Mol. Genet. Metab. 85, 2-6 (2005).
84. Trinh BC, Melhem ER, Barker PB. Multi-slice proton MR spectroscopy and diffusion-weighted imaging in methylmalonic acidemia: report of two cases and review of the literature. AJNR Am. J. Neuroradiol. 22, 831-833 (2001).
85. McGuire PJ, Lim-Melia E, Diaz GA et al. Combined liver-kidney transplant for the management of methylmalonic aciduria: a case report and review of the literature. Mol. Genet. Metab. 93, 22-29 (2008).
86. Smith WE, Millington DS, Koeberl DD. Glutaric acidemia, type I , missed by newborn screening in and Infant with dystonia following promethazine administration. Pediatrics 107, 1184-1187 (2001).
87. Kolker S, Christensen E, Leonard JV et al. Guideline for the diagnosis and management of glutaryl-CoA dehydrogenase deficiency (glutaric aciduria type I). J. Inherit. Metab. Dis. 30, 5-22 (2007).
88. Gordon N. Glutaric aciduria types I and II. Brain Dev. 28, 136-140 (2006).
89. Strauss KA, Morton DH. Type I glutaric aciduria, part 2, a modal of acute striatal necrosis. Am. J. Med. Genet. 121, 53-70 (2003).
90. Twomey EL, Naughten ER, Donoghue VB, Ryan S. Neuroimaging findings in glutaric aciduria type I. Pedriatr. Radiol. 33, 823-830 (2003).
91. Lamhonwah AM, Barankiewicz TJ, Willard HF, Mahuran DJ, Quan F, Gravel RA. Isolation of cDNA clones coding for the α and β chains of human propionyl-CoA carboxylase: chromosomal assignments and DNA polymorphisms associated with PCCA and PCCB genes. Proc. Natl Acad. Sci. USA 83, 4864-4868 (1986).
92. Delgado C, Macías C, de la Sierra García-Valdecasas M, Pérez M, del Portal LR, Jiménez LM. Subacute presentation of propionic acidemia. J. Child. Neurol. 22, 1405-1407 (2007).
93. Nyhan WL, Bay C, Beyer EW, Mazi M. Neurologic nonmetabolic presentation of propionic academia. Arch. Neurol. 56, 1143-1147 (1999).
94. Harker HE, Emhardt JD, Hainline BE. Propionic acidemia in a four-month-old male: a case study and anesthetic implications. Anesth. Analg. 91, 309-311 (2000).
95. Wolf B, Hsia YE, Sweetman L, Gravel R, Harris DJ, Nyhan WL. Propionic acidemia: a clinical update. J. Pediatr. 99, 835-846 (1981).
96. Rela M, Battula N, Madanur M et al. Auxiliary liver transplantation for propionic acidemia: a 10-year follow-up. Am. J. Transplant. 7, 2200-2203 (2007).
97. Haas RH, Marsden DL, Capistrano-Estrada S et al. Acute basal ganglia infarction in propionic acidemia. J. Child. Neurol. 10, 18-22 (1995).
98. Hamilton RL, Haas RH, Nyhan WL, Powell HC, Grafe MR. Neuropathology of propionic acidemia: a report of two patients with basal ganglia lesions. J. Child. Neurol. 10, 25-30 (1995).
99. Burlina AP, Baracchini C, Carollo C, Burlina AB. Propionic acidaemia with basal ganglia stroke: treatment of acute extrapyramidal symptoms with L-DOPA. J. Inherit. Metab. Dis. 24, 596-598 (2001).
100. Al-Essa M, Bakheet S, Patay Z et al. 18Fluoro-2-deoxyglucose (18FDG) PET scan of the brain in propionic acidemia: clinical and MRI correlations. Brain Dev. 21, 312-317 (1999).
101. Brismar J, Ozand PT. CT and MR of the brain in disorders of the propionate and methylmalonate metabolism. AJNR Am. J. Neuroradiol. 15, 1459-1473 (1994).
102. Sweetman L, Weyler W, Shafai T, Young PE, Nyhan WL. Prenatal diagnosis of propionic acidemia. JAMA 242, 1048-1052 (1979).
103. Pérez-Cerdá C, Merinero B, Martí M et al. An unusual late-onset case of propionic acidaemia: biochemical investigations, neuroradiological findings and mutation analysis. Eur. J. Pediatr. 157, 50-52 (1998).
104. Hirano, M, Pavlakis SG. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): current concepts. J. Child. Neurology 9, 4-13 (1994).
105. Kaufmann P. Cerebral lactic acidodis correlates with neurological impairment in MELAS Neurol. 62, 1297-1302 (2004).
106. Silliman S. Mendelian and mitochondrial disorders associated with stroke. J. Stroke Cerebrovasc. Dis. 11, 252-264 (2002). •• Very concise review of stroke genetics.
107. Manwaring N, Jones MM, Wang JJ et al. Population prevalence of the MELAS A3243G mutation. Mitochondrion 7, 230-233 (2007).
108. Silbert, L, Durocher, A, Biller, J. The "S" in MELAS. J. Stroke Cerebrovasc. Dis. 6, 67-71 (1996).
109. Shoffner JM, Wallace DC. Oxidative phosphorylation disease and stroke. Heart Dis. Stroke 2, 439-445 (1993).
110. Thambisetty M, Newman NJ, Glass JD, Frankel MR. A practical approach to the diagnosis and management of MELAS: case report and review. Neurologist 8302-8312 (2002). • Very good review on mitochondrial encephalopathy, lactic acidosis and stroke-like phenomenon (MELAS).
111. Yamamoto T, Beppu H, Tsubaki T. Mitochondrial encephalomyopathy: fluctuating symptoms and CT. Neurology 34, 1456-1460 (1984).
112. Yoneda M, Maeda M, Kimura H, Fujii A, Katayama K, Kuriyama M. Vasogenic edema on MELAS: a serial study with diffusion-weighted MR imaging. Neurology 53, 2182-2184 (1999).
113. Ohama E, Ohara S, Ikuta R, Tanaka K Nishizawa M, Miyatake T. Mitochondrial angiopathy in cerebral vessels of mitochondrial encephalomyopahty. Acta Neuropath. (Berl.) 74, 226-233 (1987).
114. Scaglia F, Northrop JL. The mitochondrial myopathy encephalopathy, lactic acidosis with stroke-like episodes (MELAS) syndrome: a review of treatment options. CNS Drugs 20, 443-464 (2006).
115. Lindgren V, de Martinville B, Horwich AL, Rosenberg LE, Francke U. Human ornithine transcarbamylase locus mapped to band Xp21.1 near the Duchenne muscular dystrophy locus. Science 226, 698-700 (1984).
116. Brusilow SW, Maestri NE. Urea cycle disorders: diagnosis, pathophysiology and therapy. Adv. Pediatr. 43, 127-170 (1996).
117. Hu WT, Kantarci HO, Merritt II JL et al. Ornithine transcarbamylase deficiency presenting as encephalopathy during adulthood following bariatric surgery. Arch. Neurol. 64, 126-128 (2007).
118. Maestri NE, Brusilow SW, Clissold DB, Bassett SS. Long-term treatment of girls with ornithine transcarbamylase deficiency. N. Engl. J. Med. 335, 855-859 (1996).
119. Gordon N. Ornithine transcarbamylase deficiency: a urea cycle defect. Eur. J. Paediatr. Neurol. 7, 115-121 (2003).
120. Yoshino M, Nishiyori J, Yamashita F et al. Ornithine transcarbamylase deficiency in male adolescence and adulthood. Enzyme 43, 160-168 (1990).
121. Legras A, Labarthe F, Maillot F, Garrigue MA, Kouatchet A, Ogier de Baulny H. Late diagnosis of ornithine transcarbamylase defect in three related female patients: polymorphic presentations. Crit. Care Med. 30, 241-244 (2002).
122. de Grauw TJ, Smit LM, Brockstedt M, Meijer Y, vd Klei-von Moorsel J, Jakobs C. Acute hemiparesis as the presenting sign in a heterozygote for ornithine transcarbamylase deficiency. Neuropediatrics 21, 133-135 (1990).
123. Christodoulou J, Qureshi IA, McInnes RR, Clarke JT. Ornithine transcarbamylase deficiency presenting with strokelike episodes. J. Pediatr. 122, 423-425 (1993).
124. Keegan CE, Martin DM, Quint DJ, Gorski JL. Acute extrapyramidal syndrome in mild ornithine transcarbamylase deficiency: metabolic stroke involving the caudate and putamen without metabolic decompensation. Eur. J. Pediatr. 162, 259-263 (2003).
125. Michalak A, Butterworth RF. Ornithine transcarbamylase deficiency: pathogenesis of the cerebral disorder and new prospects for therapy. Metab. Brain Dis. 12, 171-182 (1997).
126. Takanashi J, Barkovich AJ, Cheng SF, Kostiner D, Baker JC, Packman S. Brain MR imaging in acute hyperammonemic encephalopathy arising from late-onset ornithine transcarbamylase deficiency. AJNR Am. J. Neuroradiol. 24, 390-393 (2003).
127. Steiner RD, Cederbaum SD. Laboratory evaluation of urea cycle disorders. J. Pediatr. 138, S21-S29 (2001).
128. Chiong MA, Carpenter K, Christodoulou J. Low citrulline may not be diagnostic of ornithine transcarbamylase deficiency: a case report. J. Inherit. Metab. Dis. 30, 405 (2007).
129. Arranz JA, Riudor E, Rodés M et al. Optimization of allopurinol challenge: sample purification, protein intake control, and the use of orotidine response as a discriminative variable improve performance of the test for diagnosing ornithine carbamoyltransferase deficiency. Clin. Chem. 45, 995-1001 (1999).
130. Grünewald S, Fairbanks L, Genet S et al. How reliable is the allopurinol load in detecting carriers for ornithine transcarbamylase deficiency? J. Inherit. Metab. Dis. 27, 179-186 (2004).
131. Nagasaka H, Yorifuji T, Murayama K et al. Effects of arginine treatment on nutrition, growth and urea cycle function in seven Japanese boys with late-onset ornithine transcarbamylase deficiency. Eur. J. Pediatr. 165, 618-624 (2006).